Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 2 |
2018 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.
J Diabetes Complications. 2024 Jan;38(1):108650. doi: 10.1016/j.jdiacomp.2023.108650. Epub 2023 Nov 23.
J Diabetes Complications. 2024.
PMID: 38035640
Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice.
Kishi H, Usui I, Jojima T, Fujisaka S, Wakamatsu S, Mizunuma-Inoue Y, Niitani T, Sakurai S, Iijima T, Tomaru T, Tobe K, Aso Y.
Kishi H, et al. Among authors: wakamatsu s.
Int J Mol Sci. 2022 Dec 4;23(23):15309. doi: 10.3390/ijms232315309.
Int J Mol Sci. 2022.
PMID: 36499635
Free PMC article.
Item in Clipboard
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, Aso Y.
Jojima T, et al. Among authors: wakamatsu s.
Int J Cardiol. 2021 May 15;331:243-248. doi: 10.1016/j.ijcard.2021.01.063. Epub 2021 Feb 5.
Int J Cardiol. 2021.
PMID: 33556413
Clinical Trial.
Item in Clipboard
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y.
Jojima T, et al. Among authors: wakamatsu s.
Int J Mol Sci. 2019 Oct 22;20(20):5237. doi: 10.3390/ijms20205237.
Int J Mol Sci. 2019.
PMID: 31652578
Free PMC article.
Item in Clipboard
Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study.
Suzuki K, Yanagi K, Shimizu M, Wakamatsu S, Niitani T, Hosonuma S, Sagara M, Aso Y.
Suzuki K, et al. Among authors: wakamatsu s.
Endocr J. 2018 Jan 30;65(1):101-111. doi: 10.1507/endocrj.EJ17-0330. Epub 2017 Oct 25.
Endocr J. 2018.
PMID: 29070768
Free article.
Clinical Trial.
Item in Clipboard
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y.
Kato K, et al. Among authors: wakamatsu s.
Expert Opin Pharmacother. 2017 Jun;18(8):743-751. doi: 10.1080/14656566.2017.1317748. Epub 2017 Apr 21.
Expert Opin Pharmacother. 2017.
PMID: 28426260
Clinical Trial.
Item in Clipboard
Cite
Cite